glaxosmithkline plc-spon adr
Transactions by GLAXOSMITHKLINE PLC-SPON ADR (GSK) in the last 6 months
Novartis Pharma AG entered into an agreement to acquire all remaining rights to Ofatumumab from GlaxoSmithKline plc (LSE:GSK) for $1 billion on August 21, 2015. Under the terms of the agreement, Novartis will make an initial upfront payment of $300 million at closing to GlaxoSmithKline for the acquisition of the compound and a further payment of $200 million payable subject to the start of a phase III study in MS by Novartis. Upon completion of pre-determined milestones, ...
Pfizer Ireland Pharmaceuticals signed an agreement to acquire Nimenrix and Mencevax from GlaxoSmithKline plc (LSE:GSK) for £82 million on June 22, 2015. The total consideration includes some deferred consideration. Nimenrix and Mencevax reported sales of £34 million in 2014. The agreement remains subject to final European Commission approval, other regulatory approvals and other customary closing conditions. The deal is expected to be completed before the end of the ...
Perrigo Company Public Limited Company (NYSE:PRGO) entered into an agreement to acquire portfolio of well established over the counter brands from GlaxoSmithKline plc (LSE:GSK) in cash on June 2, 2015. Portfolio includes well-established European brands in the areas of nicotine replacement therapy, cold and flu, and cold sore management. The portfolio of brands recorded net sales of approximately $110 million in 2014. The deal is subject to approval by the European Commission, ...
GlaxoSmithKline plc (LSE:GSK) acquired 4.96% stake in Valneva SE (ENXTPA:VLA) from Novartis AG (SWX:NOVN) on March 3, 2015.
|AbbVie Inc||$59.77 USD||-1.81|
|Bristol-Myers Squibb Co||$57.30 USD||-1.45|
|Celgene Corp||$117.39 USD||-0.26|
|Eli Lilly & Co||$80.32 USD||-1.28|
|Medtronic PLC||$68.98 USD||-1.00|
|View Industry Companies|